[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 54 of about 54

Advertisement
4. Machado NO, Chopra PJ, Al Hamdani A: Pancreatic metastasis from colon carcinoma nine years after a hemicolectomy managed by distal pancreatectomy. A review of the literature regarding the role and outcome of pancreatic resection for colorectal metastasis. JOP; 2010;11(4):377-81
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic metastasis from colon carcinoma nine years after a hemicolectomy managed by distal pancreatectomy. A review of the literature regarding the role and outcome of pancreatic resection for colorectal metastasis.
  • CONTEXT: Pancreatic metastasis from colorectal malignancy is rare and accounts for less than 2% of all pancreatic metastases.
  • A case of colonic metastasis to the pancreas is reported and the literature is reviewed to assess the role and outcome of pancreatic resection for metastatic tumors from colorectal malignancy.
  • A postoperative staging CT scan showed no other metastases and she received 6 cycles of FOLFOX chemotherapy (folinic acid, 5-flurouracil and oxaliplatin).
  • A CT scan revealed a 6.8x4.8 cm mixed consistency lesion in the tail of the pancreas which, on fine needle aspiration cytology, was confirmed to be adenocarcinoma.
  • She underwent a distal pancreatectomy, and histopathology of the resected specimen confirmed a metastatic tumor from colon cancer.
  • She then received 5 cycles of adjuvant chemotherapy.
  • CONCLUSION: Pancreatic metastasis from colorectal malignancy is rare.
  • The time-interval between the diagnosis of colorectal cancer and the detection of pancreatic metastasis varies widely but is approximately 24 months.
  • The median survival time for post-pancreatic resection is 16 months.
  • Pancreatic resection appears to offer good palliation until recurrence of the disease occurs and the possibility of long term cure is rare.
  • [MeSH-major] Carcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Female. Humans. Prognosis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JOP. 2010;11(6):644-5; author reply 650 [21068505.001]
  • (PMID = 20601814.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 24
  •  go-up   go-down


5. Jia L, Zhang MH, Yuan SZ, Huang WG: Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice. World J Gastroenterol; 2005 Jan 21;11(3):447-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice.
  • AIM: To investigate the anti-tumor effects of antiangiogenic therapy (a combination of TNP-470, an antiangiogenic compound, with gemcitabine, an antimetabolite) on human pancreatic carcinoma xenografts and its mechanism.
  • METHODS: A surgical orthotopic implantation (SOI) model was established by suturing small pieces of SW1990 pancreatic carcinoma into the tail of pancreas in nude male mice.
  • Mice then received either single therapy (n = 24) or combined therapy (n = 32).
  • Mice receiving single therapy were randomly divided into control group, G100 group receiving 100 mg/kg gemcitabine IP on d 0, 3, 6 and 9 after transplantation, and T30 group receiving 30 mg/kg TNP-470 s.c on alternate days for 8 wk.
  • Mice receiving combined therapy were randomly divided into control group, T15 group, G50 group and combination group (TNP-470 30 mg/kg and gemcitabine 50 mg/kg).
  • Weight of transplanted tumors, the T/C rate (the rate of mean treated tumor weight to mean control tumor weight), change of body weight, metastasis rate, and 9-wk survival rate were investigated.
  • Tumor samples were taken from the control group, T30 group, G100 group and combination group.
  • RESULTS: There was a significant inhibitory effect on primary tumor growth of pancreatic carcinoma in G100 group, compared to T30 group, whereas tumor metastasis was significantly inhibited in T30 group compared to G100 group.
  • No significant inhibitory effect on tumor growth and metastasis in T15 group and G50 group.
  • However, significant anti-tumor and anti-metastatic effects were observed in the combination group with a significant improvement in survival rate.
  • The inhibitory effect on tumor growth in combination group enhanced 2 times in comparison with G50 group and 5 times in comparison with T15 group.
  • Moreover, 25% of the animals bearing tumors were cured by the combination therapy.
  • CONCLUSION: Antiangiogenic therapy shows significant anti-tumor and anti-metastatic effects, and is helpful to reduce the dosage of cytotoxic drugs and the side effects.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Carcinoma / pathology. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / pathology. Sesquiterpenes / pharmacology
  • [MeSH-minor] Animals. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / pharmacology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Cyclohexanes. Dose-Response Relationship, Drug. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Metastasis / prevention & control. Neoplasm Transplantation. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15637766.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antimetabolites, Antineoplastic; 0 / Cyclohexanes; 0 / Sesquiterpenes; 0W860991D6 / Deoxycytidine; 129298-91-5 / O-(chloroacetylcarbamoyl)fumagillol; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ PMC4205360
  •  go-up   go-down


6. Choi SH, Hwang HK, Kang CM, Lee WJ: Total pancreaticoduodenectomy and segmental resection of superior mesenteric vein-portal vein confluence with autologous splenic vein graft in mucinous cystadenocarcinoma of the pancreas. JOP; 2010;11(6):638-41
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total pancreaticoduodenectomy and segmental resection of superior mesenteric vein-portal vein confluence with autologous splenic vein graft in mucinous cystadenocarcinoma of the pancreas.
  • CONTEXT: Mucinous cystic tumors occur almost exclusively in middle-aged women and in the body or tail of the pancreas.
  • Mucinous cystadenocarcinoma, a malignant sub-type of mucinous cystic tumors, in the head of the pancreas and in a middle-aged man is extraordinary, and the prognosis and proper management of mucinous cystadenocarcinoma has not been well documented.
  • CASE REPORT: A 52-year-old male patient with a mucinous cystadenocarcinoma approximately 5.5 cm in size in the head of the pancreas underwent a total pancreaticoduodenectomy and segmental resection of the superior mesenteric vein-portal vein confluence with an autologous splenic vein graft due to tumor invasion.
  • His postoperative course was uneventful and he received adjuvant chemotherapy.
  • CONCLUSION: Mucinous cystadenocarcinoma in the head of the pancreas in a middle-aged man is an extremely rare case.
  • [MeSH-major] Cystadenocarcinoma, Mucinous / surgery. Mesenteric Veins / surgery. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods. Portal Vein / surgery. Splenic Vein / transplantation
  • [MeSH-minor] Humans. Male. Middle Aged. Tomography, X-Ray Computed. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21068503.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Doi M, Imai T, Shichiri M, Tateno T, Fukai N, Ozawa N, Sato R, Teramoto K, Hirata Y: Octreotide-sensitive ectopic ACTH production by islet cell carcinoma with multiple liver metastases. Endocr J; 2003 Apr;50(2):135-43
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Octreotide-sensitive ectopic ACTH production by islet cell carcinoma with multiple liver metastases.
  • We report a 21-year-old woman with ectopic ACTH syndrome due to islet cell carcinoma with multiple liver metastases.
  • She was found to have multiple masses in the liver and a solid mass in the tail of pancreas by abdominal computerized tomography scanning.
  • Treatment with octreotide successfully reduced elevated plasma ACTH and cortisol levels, and she received frequent transhepatic arterial embolization and chemotherapy.
  • The primary pancreatic tumor was surgically removed, revealing islet cell carcinoma which contained high content of ACTH (100 microg/g wet weight) and abundantly expressed proopiomelanocortin and somatostatin receptor subtype-2 mRNAs as determined by Northern blot analysis.
  • However, progressive enlargement of multiple liver metastases refractory to chemotherapy led her to decide on total hepatectomy and liver transplantation from her father.
  • However, metastases developed to the mediastinal and paraaortic lymph nodes as detected by 111[In] pentetreotide scintigraphy.
  • This case of a young female patient with ectopic ACTH-producing islet cell carcinoma of the pancreas was quite unique in that she survived for 5 years despite the acute onset and rapid progression of the multiple liver metastases at least in part due to the long-lasting favorable response to octreotide and living-related liver transplantation.
  • [MeSH-major] ACTH Syndrome, Ectopic / drug therapy. ACTH Syndrome, Ectopic / etiology. Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Islet Cell / complications. Carcinoma, Islet Cell / secondary. Liver Neoplasms / secondary. Octreotide / therapeutic use. Pancreatic Neoplasms / complications
  • [MeSH-minor] Adult. Female. Hepatectomy. Humans. Liver Transplantation. Living Donors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12803233.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


8. Wu G, Zhou X, Huang M: [Electrochemical therapy and implanted ports treatment for unresectable carcinoma of body and tail of pancreas]. Zhonghua Wai Ke Za Zhi; 2001 Aug;39(8):596-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Electrochemical therapy and implanted ports treatment for unresectable carcinoma of body and tail of pancreas].
  • OBJECTIVE: To examine the efficacy and safety of electrochemical therapy (ECT) in treatment of patients with unresectable carcinoma of the body and tail of pancreas.
  • METHODS: A total of 18 patients (14 men and 4 women; mean age 57.7) with unresectable carcinoma of the body and tail of pancreas were treated by ECT between May 1989 and June 1996 in our hospital (group A).
  • Another 16 patients (12 men and 4 women; mean age 60.3) were treated by ECT plus intraperitoneal chemotherapy between July 1996 and June 1999 (group B).
  • Pain was determined by using a 10-point visual analog pain scale (VAS) before and after the treatment, life quality periodically assessed according to the 5-step scale system, and tumor size measured using CT or MRI.
  • RESULTS: All the patients were followed up for 5-30 months (mean = 10 months), showing that there were no operative deaths and such complications such as pancreatic fistula and bleeding in both groups.
  • The tumor size in both groups was decreased to some degree.
  • In group A, the VAS basal score was reduced from 7.4 +/- 1.7 before to 2.66 +/- 1.05 after the treatment and the peak VAS from 9.3 +/- 0.9 to 3.71 +/- 0.96 (P < 0.05).
  • CONCLUSIONS: ECT is a safe and effective procedure for treatment of unresectable carcinoma of the body and tail of pancreas and in relieving its pain and improving the life quality of patients.
  • Supplementary injection of chemical drugs through drug delivery pump is helpful for control of ascites.
  • [MeSH-major] Electric Stimulation Therapy. Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11758195.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Ohge H, Sueda T: Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas. J Gastrointest Surg; 2009 Jan;13(1):85-92
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.
  • BACKGROUND: Few patients with pancreatic body or tail carcinoma are candidates for surgical resection, and the efficacy of postoperative adjuvant chemotherapy for patients with pancreatic body or tail carcinoma has not been elucidated.
  • The aim of this study was to determine the effect of adjuvant gemcitabine and S-1 therapy for patients with adenocarcinoma of the body or tail of the pancreas who had undergone surgical resection by distal pancreatectomy.
  • MATERIALS AND METHODS: Medical records of 34 patients with pancreatic body or tail carcinoma who underwent surgical resection were reviewed retrospectively.
  • Eighteen patients received postoperative adjuvant gemcitabine and S-1 chemotherapy.
  • Overall, 1-, 2-, and 5-year survival rates were 69%, 40%, and 25%, respectively (median survival time, 14.4 months).
  • Univariate analysis revealed that adjuvant gemcitabine plus S-1 chemotherapy, blood transfusion, splenic artery invasion, lymph node metastasis, surgical margin status, and International Union Against Cancer stage were associated significantly with long-term survival (P < 0.05).
  • Furthermore, use of a Cox proportional hazards regression model indicated that adjuvant gemcitabine plus S-1 chemotherapy and absence of lymph node metastasis were significant independent predictors of a favorable prognosis (P < 0.05).
  • CONCLUSION: Postoperative adjuvant gemcitabine plus S-1 chemotherapy may improve survival after surgical resection for pancreatic body or tail carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Oxonic Acid / therapeutic use. Pancreatectomy / methods. Pancreatic Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Drug Combinations. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Ribonucleotide Reductases / antagonists & inhibitors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):534-41 [18026816.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] Langenbecks Arch Surg. 2000 Jan;385(1):14-20 [10664114.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Ann Surg Oncol. 2004 Jul;11(7):644-9 [15197014.001]
  • [Cites] Surgery. 2006 Sep;140(3):448-53 [16934608.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2240-5 [8635090.001]
  • [Cites] Am J Surg. 2005 Mar;189(3):278-82 [15792750.001]
  • [Cites] Br J Surg. 1997 Aug;84(8):1090-2 [9278647.001]
  • [Cites] J Surg Oncol. 2000 May;74(1):36-40 [10861607.001]
  • [Cites] Pancreas. 2006 Aug;33(2):142-7 [16868479.001]
  • [Cites] J Am Coll Surg. 1997 Sep;185(3):255-9 [9291403.001]
  • [Cites] Am J Surg. 2008 Jun;195(6):757-62 [18367131.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1372-81 [15812554.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):946-52; discussion 952 [14675703.001]
  • [Cites] Surgery. 2005 Nov;138(5):962-3 [16291404.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):485-90 [16615151.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):46-51 [17592290.001]
  • [Cites] J Am Coll Surg. 2007 Feb;204(2):244-9 [17254928.001]
  • [Cites] Pancreas. 1996 May;12(4):357-61 [8740402.001]
  • [Cites] Ann Surg. 1996 May;223(5):506-11; discussion 511-2 [8651741.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2897-902 [16782929.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1575-9 [16721372.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Pancreas. 2003 Apr;26(3):243-9 [12657950.001]
  • [Cites] Surgery. 2006 Mar;139(3):288-95 [16546491.001]
  • [Cites] J Gastrointest Surg. 2005 Sep-Oct;9(7):922-7 [16137585.001]
  • (PMID = 18704593.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / Ribonucleotide Reductases
  •  go-up   go-down


10. Ogawa B, Okinaga K, Obana K, Nakamura K, Hattori T, Ito T, Yanagawa Y, Tanaka F, Imamura T: Pancreatoblastoma treated by delayed operation after effective chemotherapy. J Pediatr Surg; 2000 Nov;35(11):1663-5
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatoblastoma treated by delayed operation after effective chemotherapy.
  • Computed tomography scan showed a 10- x 8- x 7-cm mass occupying both the head and body of the pancreas.
  • Results of open biopsy of the tumor showed pancreatoblastoma.
  • Chemotherapy was administered using the new A-1 regimen consisting of cyclophosphamide, etoposide, pirarubicin, and cisplatin.
  • After 3 cycles of chemotherapy, the size of the tumor was reduced to 5 x 4 x 3 cm, the portal vein became patent, and the AFP value decreased to 98.1 ng/mL.
  • Total removal of the tumor was performed leaving the head and tail of the pancreas.
  • Postoperative chemotherapy continued for 2 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / surgery. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Biopsy, Needle. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Pancreatectomy / methods. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11083448.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; D58G680W0G / pirarubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Masuda T, Kuwahara A: [A long-term survival case of unresectable malignant pancreatic endocrine tumor successfully treated with systemic chemotherapy]. Gan To Kagaku Ryoho; 2008 May;35(5):833-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survival case of unresectable malignant pancreatic endocrine tumor successfully treated with systemic chemotherapy].
  • Computed tomography showed a solid tumor in the tail of the pancreas with multiple liver tumors.
  • We diagnosed him as unresectable pancreatic tail cancer with multiple liver metastases at first, so systemic chemotherapy using UFT was performed.
  • Gradually, liver metastases were slightly reduced, and tumor markers (CEA, CA19-9) decreased to the normal range.
  • In April 2001, percutaneous transhepatic tumor biopsy was performed.
  • Histopathological examination revealed a malignant pancreatic endocrine tumor.
  • But because tumors had gradually grown since October 2003, the chemotherapy with S-1 was followed by gemcitabine (GEM).
  • The patient has now survived for 7.5 years while receiving the combined chemotherapy of S-1/GEM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Islet Cell / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Combinations. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487924.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


12. Wato M, Inaba T, Ishikawa H, Ishikawa S, Baba N, Miyoshi M, Senoh T, Nagano T, Takaguchi K, Watanabe S, Kawai K: [A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer]. Nihon Shokakibyo Gakkai Zasshi; 2010 Oct;107(10):1676-85
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer].
  • A 63-year-old man with Stage IVa pancreas tail cancer was admitted for a distal pancreatectomy and splenectomy; adjuvant chemotherapy with gemcitabine was also administered.
  • The chemotherapy was terminated after 16 courses due to hemolytic anemia, thrombocytopenia and renal dysfunction.
  • Physicians should be cautious of hemolytic uremic syndrome as a possible adverse reaction to gemcitabine and be aware that tests are needed for its early detection.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Deoxycytidine / analogs & derivatives. Hemolytic-Uremic Syndrome / chemically induced. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / adverse effects. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hemolytic uremic syndrome.
  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20938119.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


13. Mizutani S, Inada T, Fukutomi K, Igarashi S, Ogata Y: [A patient with gastric cancer with para-aortic lymph node metastases surviving for 9 years after effective preoperative chemotherapy and radical operation]. Gan To Kagaku Ryoho; 2000 Aug;27(9):1433-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with gastric cancer with para-aortic lymph node metastases surviving for 9 years after effective preoperative chemotherapy and radical operation].
  • A 63-year-old male patient with type 3 advanced gastric cancer was referred to our hospital.
  • Preoperative examination by CT-scan revealed swollen para-aortic lymph nodes and cancer invasion to the pancreas.
  • Immediately after the chemotherapy, the patient underwent total gastrectomy, splenctomy, left-adrenectomy and resection of the body and tail of the pancreas, along with para-aortic lymph node dissection.
  • Microscopic examination revealed that the tumor was a moderately differentiated tubular adenocarcinoma, which displayed invasion to the pancreas with lymph node metastasis up to the level 3 lymph node.
  • Histologically, the effect of preoperative chemotherapy showed a grade 2 effect on the main tumor, but a grade 3 chemotherapeutic effect was observed at the para-aortic lymph nodes.
  • In this case, it is considered that the preoperative chemotherapy by 5-FU and potentially curative radical operation yielded a good outcome.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Fluorouracil / administration & dosage. Gastrectomy. Lymph Nodes / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aorta. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Pancreatic Neoplasms / pathology. Preoperative Care. Survivors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10969602.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Nakayama N, Tanabe S, Koizumi W, Higuchi K, Sasaki T, Nakatani K, Shimoda T, Nishimura K, Kobayashi N, Mitomi H, Saigenji K: [A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor]. Gan To Kagaku Ryoho; 2006 Nov;33(11):1641-4
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor].
  • Computed tomography and ultrasonography of the abdomen revealed bilateral ovarian tumors, massive ascites, and bilateral pleural effusion.
  • Type IV advanced gastric cancer was diagnosed on upper gastrointestinal endoscopy.
  • She received 3 courses of combination chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin.
  • Surgery (total gastrectomy, resection of the tail of the pancreas, lymph-node dissection, total hysterectomy, and adnexectomy) was performed, and the patient was discharged.
  • Chemotherapy was repeated after surgery.
  • Lymph-node metastasis recurred 1 year 8 months after the start of chemotherapy.
  • Treatment was switched to irinotecan plus cisplatin, and the lymph nodes shrank.
  • Two years 10 months after starting chemotherapy, abdominal and low back pain developed.
  • The patient responded to radiotherapy with chemotherapy (cisplatin plus 5-fluorouracil).
  • Subsequently, abdominal computed tomography showed lymph-node swelling, multiple metastases to the liver, ascites, and a right pleural effusion.
  • She was readmitted to the hospital and received intraperitoneal chemotherapy with cisplatin.
  • The patient survived for about 3 years 4 months after the start of treatment.
  • Chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin may thus be an effective therapeutic option in patients who have advanced gastric cancer with peritoneal dissemination.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Krukenberg Tumor / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Pleurisy / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Gastrectomy. Humans. Hysterectomy. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Methotrexate / administration & dosage. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / surgery. Pancreatectomy. Survivors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17108732.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


15. Xie YB, Wang CF, Li CR, Shan Y, Zhao DB, Tian YT, Zhao P: [Influence of adjuvant therapy on survival of patients with pancreatic carcinoma of body and tail: a report of 137 cases]. Zhonghua Yi Xue Za Zhi; 2009 Apr 14;89(14):951-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Influence of adjuvant therapy on survival of patients with pancreatic carcinoma of body and tail: a report of 137 cases].
  • OBJECTIVE: To investigate the effect of adjuvant therapy on the treatment of carcinoma of the body and tail of pancreas.
  • METHODS: The clinical data of 137 patients with carcinoma of the body and tail of pancreas, 91 males and 46 females, aged 58.9 (24 - 76), of which 38 underwent radical resection, 24 underwent palliative resection, and 75 did not undergo resection, and 58 of which underwent adjuvant therapy, were analyzed.
  • The median survival time (MST) was 8 months for the whole group, 15 months for the radical resection group, 8 months for the palliative resection group, and 6 months for the no resection group.
  • The 3-year survival rate was 13.9% for the patients undergoing adjuvant therapy and 7.2% for those without adjuvant therapy, and the MST was 11 months for those undergoing adjuvant therapy, and 5 months for those without adjuvant therapy.
  • Intra-arterial therapy and radiation therapy were protective factors for those whose cancerous tissues were not radically resected (OR = 1.56, 95% CI: 1.04 - 2.35, P = 0.033).
  • CONCLUSION: Adjuvant therapy significantly improves the survival of the patients with pancreatic carcinoma of the body and tail.
  • The clinical effect of intra-arterial therapy is better than those of radiation therapy and chemotherapy.
  • [MeSH-major] Neoadjuvant Therapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671304.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


16. Kaushal V, Goel A, Rattan KN, Yadav R, Mathur SK: Pancreatoblastoma. Indian J Pediatr; 2001 Nov;68(11):1075-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatoblastoma is an extremely rare pancreatic tumor in childhood, comprising 0.5% of pancreatic non endocrine tumors.
  • Exploratory laparotomy revealed a large mass, arising from body and tail of pancreas, not infiltrating the adjacent structures.
  • Complete excision of the mass along with removal of body and tail of pancreas was done.
  • The role of adjuvant chemotherapy or radiotherapy is still under discussion due to small number of patients treated as yet.
  • [MeSH-major] Pancreatectomy / methods. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Biopsy, Needle. Child. Follow-Up Studies. Humans. Laparotomy / methods. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trop Gastroenterol. 1998 Apr-Jun;19(2):67-9 [9752756.001]
  • [Cites] Cancer. 1987 Oct 15;60(8):1734-6 [3115557.001]
  • [Cites] Gastroenterol Clin Biol. 1997;21(11):880-3 [9587540.001]
  • [Cites] Langenbecks Arch Chir Suppl Kongressbd. 1996;113:1040-2 [9101776.001]
  • [Cites] J Pediatr Surg. 2000 Nov;35(11):1663-5 [11083448.001]
  • [Cites] Cancer. 1984 Feb 15;53(4):963-9 [6141001.001]
  • [Cites] Minerva Chir. 1996 Sep;51(9):729-35 [9082240.001]
  • [Cites] Arch Pathol Lab Med. 1986 Jul;110(7):650-2 [3013120.001]
  • [Cites] Cancer. 1977 Jan;39(1):247-54 [188539.001]
  • [Cites] Eur J Pediatr Surg. 1996 Dec;6(6):369-72 [9007475.001]
  • [Cites] Med Pediatr Oncol. 1996 Sep;27(3):193-7 [8699999.001]
  • [Cites] Surgery. 1984 Apr;95(4):505 [6710348.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1994 Sep;54(3):198-203 [7954063.001]
  • [Cites] J Pediatr Surg. 1997 Nov;32(11):1612-5 [9396538.001]
  • (PMID = 11770246.001).
  • [ISSN] 0019-5456
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


17. Yin WH, Yu GY, Ma Y, Rao HL, Lin SX, Shao CK, Liang Q, Guo N, Chen GQ, Zhou W, Zhao T, Zhu MG: [Follicular dendritic cell sarcoma: a clinicopathologic analysis of ten cases]. Zhonghua Bing Li Xue Za Zhi; 2010 Aug;39(8):522-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the clinicopathologic features of follicular dendritic cell sarcoma (FDCS) and its differential diagnosis.
  • Six of them were located in cervical and peritoneal lymph nodes and four in extranodal sites (including tonsil, pelvic cavity, tail of pancreas and spleen).
  • Histologically, the tumor cells had whorled, storiform or diffuse growth patterns.
  • Multinucleated tumor giant cells and intranuclear pseudoinclusions were occasionally seen.
  • There was a sprinkling of small lymphocytes and neutrophils within the tumor as well as in the perivascular region.
  • Immunohistochemical study showed that the tumor cells were diffusely or focally positive for CD21, CD23, CD35 and D2-40, but negative for LCA, CD20, CD3, CD1a, HMB45 and CK.
  • The remaining 5 patients were alive and disease-free after surgical excision (+/- chemotherapy and radiotherapy).
  • CONCLUSIONS: FDCS is a rare low to intermediate-grade malignant tumor.
  • Appropriate application of FDC markers, such as CD21, CD35 and D2-40, would be helpful for arriving at a correct diagnosis.
  • Most cases are associated with good prognosis after surgical treatment, with or without chemotherapy and radiotherapy.
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived / metabolism. Dendritic Cell Sarcoma, Interdigitating / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Meningioma / pathology. Middle Aged. Nasopharyngeal Neoplasms / pathology. Paraneoplastic Syndromes / complications. Pemphigus / complications. Receptors, Complement 3b / metabolism. Receptors, Complement 3d / metabolism. Receptors, IgE / metabolism. Young Adult

  • Genetic Alliance. consumer health - TEN.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21055030.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Receptors, Complement 3b; 0 / Receptors, Complement 3d; 0 / Receptors, IgE; 0 / monoclonal antibody D2-40
  •  go-up   go-down


18. Makino H, Kametaka H, Yasuno K, Koyama T, Seike K: [The effectiveness of reduction surgery and gemcitabine for multiple bowel obstructions due to peritoneal dissemination of pancreatic carcinoma with liver metastasis--a case report]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2416-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The effectiveness of reduction surgery and gemcitabine for multiple bowel obstructions due to peritoneal dissemination of pancreatic carcinoma with liver metastasis--a case report].
  • Computed tomography (CT) revealed pancreatic carcinoma invading to spleen with liver metastasis and peritoneal dissemination.
  • The pancreatic carcinoma was located at the tail of pancreas invading to spleen with liver metastasis.
  • We performed a distal pancreatectomy, partial hepatectomy, partial resection of the stomach, five-partial resection of the small intestine, right colectomy and sigmoidectomy.
  • No operative complication was seen, and we started chemotherapy using gemcitabine soon after the operation.
  • After 3 months, the tumor markers normalized.
  • The removal of bowel obstruction by operation enabled us to perform intestinal nutrition and sufficient chemotherapy, which may lead to the favorable prognosis.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Intestinal Obstruction / therapy. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology. Peritoneal Neoplasms / complications. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037441.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


19. Eyigor C, Pirim A, Uyar M: Should interventional pain management in patients with pancreatic cancer be guided by tumor localization? J BUON; 2010 Oct-Dec;15(4):715-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should interventional pain management in patients with pancreatic cancer be guided by tumor localization?
  • PURPOSE: to investigate the impact of pancreatic cancer localization in relation to the response to different interventional pain management methods and determine the method most suitable for satisfactory pain control.
  • Patients were allocated into 2 groups according to the tumor localization, namely group 1 (n=61; patients with pancreatic cancer confined to the head of pancreas), and group 2 (n=55; patients with pancreatic cancer confined to the body or tail of pancreas).
  • CONCLUSION: pain palliation could be achieved by sympathetic block in patients with cancer localized in the head of pancreas while patients with tumor localized in the body and tail experienced sufficient pain palliation by spinal analgesia rather than sympathetic block.
  • [MeSH-major] Anesthetics, Local / therapeutic use. Pain Measurement. Pain, Intractable / drug therapy. Pancreatic Neoplasms / complications
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Nerve Block. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21229635.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anesthetics, Local
  •  go-up   go-down


20. Kinoshita K, Minami T, Ohmori Y, Kanayama S, Yoshikawa K, Tsujimura T: Curative resection of a small cell carcinoma of the pancreas: report of a case of long survival without chemotherapy. J Gastroenterol Hepatol; 2004 Sep;19(9):1087-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curative resection of a small cell carcinoma of the pancreas: report of a case of long survival without chemotherapy.
  • Computed tomography and magnetic resonance imaging showed a slightly enhanced heterogeneous mass, measuring about 5 cm in diameter, adjacent to the pancreas tail and spleen.
  • On abdominal angiography the tumor was found to be fed by the splenic artery, and no encasement was observed.
  • At operation the tumor was connected to the pancreas tail and attached to the spleen, and no metastasis was evident.
  • On histological examination the tumor cells had no ductal or architectural organization and were continuous to the normal pancreatic tissues.
  • Immunohistochemistry indicated that the tumor cells were positive for keratin and epithelial membrane antigen, but negative for chromogranin A, vimentin, alpha1-antitrypsin and alpha1-antichymotrypsin.
  • The tumor was diagnosed as a small cell carcinoma of the pancreas, which is a rare disease.
  • In previously reported cases curative resection of the tumor had not been possible because of its rapid progression and metastasis, and the prognosis is generally very poor.
  • In our case, however, curative resection of the tumor was done, and the patient is healthy with no signs of recurrence for 56 months after the operation and with no additional therapy.
  • [MeSH-major] Carcinoma, Small Cell / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Diagnosis, Differential. Diagnostic Imaging. Humans. Immunohistochemistry. Male. Pancreatectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15304133.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 33
  •  go-up   go-down


21. Schütt M, Lorch H, Krüger S, Klingenberg RD, Peters A, Klein HH: [Recurrent hypoglycemia caused by malignant insulinoma: chemoembolization as a therapeutic option]. Med Klin (Munich); 2001 Oct 15;96(10):632-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent hypoglycemia caused by malignant insulinoma: chemoembolization as a therapeutic option].
  • Ultrasound and computertomography of the abdomen showed a huge inhomogeneous mass in the tail of pancreas and multiple lesions in the liver, respectively.
  • Core needle biopsies revealed typical histopathological findings of a neuroendocrine carcinoma.
  • TREATMENT AND COURSE: Eight cycles of chemotherapy were given using streptozotocin/doxorubicin for three cycles and streptozotocin/5-fluorouracil for the remaining therapy over a period of 16 months resulting in a reduction in size of liver metastases and improvement of symptoms.
  • Following 6 months without any therapy new episodes of severe hypoglycemia and progression of the liver metastases occurred.
  • Despite seven further cycles of chemotherapy and additional treatment with diazoxide/octreotide the patient remained hypoglycemic and continuous glucose infusions became necessary.
  • CONCLUSION: Chemoembolization is an effective possibility in the palliative treatment of advanced malignant insulinoma.
  • [MeSH-major] Chemoembolization, Therapeutic. Hypoglycemia / etiology. Insulinoma / therapy. Liver Neoplasms / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Fatal Outcome. Female. Humans. Recurrence


25. Matthes K, Mino-Kenudson M, Sahani DV, Holalkere N, Fowers KD, Rathi R, Brugge WR: EUS-guided injection of paclitaxel (OncoGel) provides therapeutic drug concentrations in the porcine pancreas (with video). Gastrointest Endosc; 2007 Mar;65(3):448-53
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EUS-guided injection of paclitaxel (OncoGel) provides therapeutic drug concentrations in the porcine pancreas (with video).
  • BACKGROUND: OncoGel (ReGel/paclitaxel) is an intralesional injectable formulation of the chemotherapeutic drug, paclitaxel, for local tumor management.
  • OBJECTIVE: The aim of this study was to determine if a minimally invasive EUS-guided injection of paclitaxel, bound to a thermosensitive gel carrier, would lead to therapeutic tissue concentrations of the chemotherapeutic agent in the porcine pancreas.
  • DESIGN: Eight Yorkshire breed pigs were sedated by general anesthesia and OncoGel was injected, under EUS-guidance, with a 22-gauge needle into the tail of the pancreas.
  • The outcome was determined by gross and microscopic evidence of inflammation of the pancreas, clinical tolerance, and quantitation of tissue paclitaxel concentrations.
  • An intrapancreatic hyperechoic focus, with an average diameter of 2.1 +/- 0.8 cm, was visible by EUS, and a hypodense area in the tail of the pancreas was visible by contrast CT.
  • Clinically, the animals appeared to tolerate the procedure without sequelae.
  • At euthanasia, a depot of OncoGel, with an average diameter of 14.7 +/- 5.0 mm), was located both grossly and histologically in the pancreatic tail.
  • After 14 days, clinically significant tissue concentrations of paclitaxel were detected at a distance of 30 to 50 mm from the depot in the animals that underwent an injection of 3 and 4 mL of the agent (n = 2).
  • CONCLUSIONS: The EUS-guided injection of OncoGel into the pancreas of the pig provided high and sustained localized concentrations of paclitaxel.
  • This technique is a potential minimally invasive local treatment option for unresectable pancreatic tumors.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Endosonography / methods. Paclitaxel / administration & dosage. Pancreas. Video Recording
  • [MeSH-minor] Animals. Chromatography, High Pressure Liquid. Dose-Response Relationship, Drug. Female. Injections, Intralesional. Male. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / metabolism. Swine. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2007 Mar;65(3):454-6 [17173918.001]
  • (PMID = 17173909.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


26. Yoneda S, Yoshiji H, Kuriyama S, Kojima H, Houki N, Matsumoto S, Nakajima Y, Tsutsumi M, Fukui H: Stage I mantle-cell lymphoma that was difficult to differentiate from abdominal tuberculous lymphadenitis and metastatic pancreatic cancer. J Gastroenterol; 2002;37(10):859-62
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I mantle-cell lymphoma that was difficult to differentiate from abdominal tuberculous lymphadenitis and metastatic pancreatic cancer.
  • Abdominal ultrasonography and enhanced computed tomography scanning revealed many enlarged lymph nodes, mainly around the pancreas tail and the hilus of the spleen.
  • Because we could not reach a final diagnosis, an exploratory laparotomy was performed.
  • After chemotherapy combined with radiotherapy, the lymph-node swelling had disappeared.
  • Herein, we report this case of stage-I mantle cell lymphoma that was difficult to differentiate from metastatic pancreatic cancer and abdominal tuberculous lymphadenitis.
  • [MeSH-major] Lymphoma, Mantle-Cell / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / secondary. Tuberculosis, Lymph Node / diagnosis
  • [MeSH-minor] Abdomen / ultrasonography. Diagnosis, Differential. Humans. Lymph Nodes / pathology. Male. Middle Aged. Radiography, Abdominal. Tomography, X-Ray Computed


27. Yusuf TE, Matthes K, Brugge WR: EUS-guided photodynamic therapy with verteporfin for ablation of normal pancreatic tissue: a pilot study in a porcine model (with video). Gastrointest Endosc; 2008 May;67(6):957-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EUS-guided photodynamic therapy with verteporfin for ablation of normal pancreatic tissue: a pilot study in a porcine model (with video).
  • BACKGROUND: EUS-guided photodynamic therapy (PDT) with the photosensitizing agent porfimer sodium has been shown to be effective in ablation of pancreatic tissue.
  • INTERVENTIONS: The tail of the pancreas was located with EUS and was used to guide the placement of a light catheter.
  • The pancreatic tail was exposed to 10, 15, or 20 minutes of laser light (689 nm).
  • MAIN OUTCOME MEASUREMENTS: Follow-up abdominal CT, liver and renal function tests, and serum pancreatic enzymes levels were performed.
  • Histology of the pancreas was obtained 7 days after the procedure on necropsy.
  • RESULTS: Localized tissue necrosis within the pancreatic tail (range 6.6-30.5 mm in diameter) was seen in all animals.
  • The diameter of the necrotic tissue was directly related to the dose of light.
  • LIMITATIONS: Normal animal model (lack of malignant tissue).
  • CONCLUSIONS: EUS-guided PDT of porcine pancreas with verteporfin achieved localized pancreatic tissue ablation in a dose-related fashion.
  • [MeSH-major] Catheter Ablation / methods. Endosonography / methods. Pancreatic Neoplasms / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage. Porphyrins / administration & dosage
  • [MeSH-minor] Animals. Disease Models, Animal. Dose-Response Relationship, Drug. Follow-Up Studies. Injections, Intravenous. Pilot Projects. Prospective Studies. Swine. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2008 May;67(6):961-3 [18440386.001]
  • (PMID = 18178203.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Porphyrins; 129497-78-5 / verteporfin
  •  go-up   go-down


28. Sanyal S, Kaman L, Sinha SK: Splenic metastasis from esophageal cancer: report of a case. Surg Today; 2005;35(11):988-90
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We herein report the case of a 25-year-old woman who underwent a transhiatal esophagectomy and adjuvant radiotherapy and chemotherapy for squamous cell carcinoma of the lower third of the esophagus with pN1 lymph node metastasis.
  • Fifteen months following surgery she was found to have splenic metastasis infiltrating the tail of the pancreas at the hilum.
  • A splenectomy, distal pancreatectomy, and resection of the splenic flexure with colocolic anastomosis were performed.
  • A histological examination of the resected specimen showed squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms / pathology. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1963 Jul;40:58-66 [13933237.001]
  • [Cites] World J Surg. 1985 Jun;9(3):468-76 [4040300.001]
  • [Cites] Surg Today. 1994;24(5):410-4 [8054811.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1336-7 [14571731.001]
  • [Cites] Cancer. 1987 Jul 1;60(1):100-2 [3581023.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):526-30 [10747308.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Dec;22(6):1011-3 [12467831.001]
  • (PMID = 16249859.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


29. Tran TH, Pathak RD, Basa AL: Metastatic insulinoma: case report and review of the literature. South Med J; 2004 Feb;97(2):199-201
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for metastatic insulinoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal computed tomographic scan demonstrated a 5 x 4-cm mass in the tail of the pancreas and many liver metastases.
  • She underwent resection of the pancreatic mass, radiofrequency ablation, and cauterization of hepatic lesions.
  • Histology confirmed pancreatic insulinoma.
  • Surgery is the only curative treatment.
  • Octreotide can be used to control hormone secretion and tumor growth.
  • Other treatments include hepatic embolization, radiotherapy, chemotherapy, and liver transplantation.
  • [MeSH-major] Insulinoma / pathology. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology


30. Nakamura S, Yata K, Jinno T, Harada T, Fujii S, Miki H, Nakano A, Kagawa K, Takeuchi K, Ozaki S, Abe M, Matsumoto T: [Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy]. Rinsho Ketsueki; 2010 Aug;51(8):690-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].
  • A 67-year-old man was diagnosed with multiple myeloma IgA-lambda type, Durie-Salmon classification stage IIIA in October 2001.
  • He received five courses of induction chemotherapy consisting of vincristine, doxorubicin and dexamethasone and then underwent high dose chemotherapy followed by autologous stem cell transplantation in March 2003.
  • He achieved partial response, but then relapsed after treatment with thalidomide and was admitted to our hospital in June 2007.
  • The patient was complicated by tumor lysis syndrome (TLS) after receiving bortezomib therapy twice.
  • Computed tomography after bortezomib therapy showed the rapid appearance of tumors in the right upper lobe of the lung, tail of the pancreas and the spleen.
  • This case suggested that metabolic acidosis was caused by TLS, while poorly controlled diabetes, secondary hemochromatosis due to transfusion, and breakthrough zygomycosis during antifungal therapy were thought to be factors contributing to the development of zygomycosis.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Boronic Acids / adverse effects. Boronic Acids / therapeutic use. Multiple Myeloma / complications. Multiple Myeloma / drug therapy. Pyrazines / adverse effects. Pyrazines / therapeutic use. Zygomycosis / etiology. Zygomycosis / pathology
  • [MeSH-minor] Acidosis / etiology. Aged. Antifungal Agents / adverse effects. Antifungal Agents / therapeutic use. Bortezomib. Echinocandins / adverse effects. Echinocandins / therapeutic use. Fatal Outcome. Humans. Lipopeptides / adverse effects. Lipopeptides / therapeutic use. Male. Pyrimidines / adverse effects. Pyrimidines / therapeutic use. Triazoles / adverse effects. Triazoles / therapeutic use. Tumor Lysis Syndrome / etiology. Voriconazole

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Zygomycosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20805677.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Echinocandins; 0 / Lipopeptides; 0 / Pyrazines; 0 / Pyrimidines; 0 / Triazoles; 69G8BD63PP / Bortezomib; JFU09I87TR / Voriconazole; R10H71BSWG / micafungin
  •  go-up   go-down


31. Gyorffy H, Tihanyi T, Gyökeres T, Zsirka-Klein A, Kádár P, Kaszás I, Kovács M: [Pancreas pseudocyst or metastasis?]. Orv Hetil; 2005 Oct 23;146(43):2223-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreas pseudocyst or metastasis?].
  • [Transliterated title] Pancreas-pseudocysta vagy metasztázis?
  • By imaging techniques (abdominal US and CT scan) a cystic lesion, measuring 40 x 35 x 30 mm in diameter was found, and was diagnosed as pseudocyst in the region of the tail of the pancreas.
  • The lesion did not improve and the second CT scan suggested a suspicion of pancreatic cystadenoma.
  • The tumour, however, was found independent of the pancreas (90 x 80 x 50 mm).
  • Both histologically and immunohistochemically the lesion proved to be the metastasis of a germ cell (yolk-sac) tumour.
  • Following the morphological diagnosis, detailed urological and medical check up was performed.
  • A previously nonpalpable small tumour was found in the left testis which was radically resected.
  • The testicular tumour measuring 9 x 9 x 5 mm in diameter was diagnosed as embryonal carcinoma.
  • Later on the patient underwent chemotherapy.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / secondary. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / secondary. Pancreatic Pseudocyst / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323569.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


32. Matsumura T, Ohzato H, Yamamoto T, Ota K, Mabuchi E, Miwa H, Ikeda H, Fukunaga M, Furukawa H: [A case of postoperative brain metastasis originated from pancreatic cancer which was successfully treated by resection and postoperative irradiation]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2433-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of postoperative brain metastasis originated from pancreatic cancer which was successfully treated by resection and postoperative irradiation].
  • We report a case of metastatic brain tumor originated from pancreatic cancer, which might be clinically considered as rare and has been reported as a remarkably poor-prognostic disease.
  • A 64-year-old male underwent pancreas tail resection for pancreatic cancer (R0 resection).
  • Histological study revealed an invasive ductal carcinoma (T4N2M0, fStage IVb).
  • After 7 courses of S-1 chemotherapy, a follow-up CT demonstrated lymph node recurrence in cervical and mediastinum region.
  • S-1 administration was stopped and irradiation to these sites (60 Gy) resulted in PR.
  • Postoperatively, hemicereberal irradiation (30 Gy) was performed.
  • The patient was alive with abdominal lymph node recurrence for 22 months after distal pancreatectomy.
  • It was concluded from these findings that irradiation to systemic recurrence originated from pancreatic cancer might be effective as well as chemotherapy.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy. Carcinoma, Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Combinations. Humans. Male. Middle Aged. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037447.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 9
  •  go-up   go-down


33. Bombardieri T, Strati V, Cafiero C, Palmanova A, Vasile R: [Carcinoma of the pancreatic body and tail]. Chir Ital; 2001 Sep-Oct;53(5):681-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma of the pancreatic body and tail].
  • [Transliterated title] Il carcinoma del corpo-coda pancreatico.
  • Carcinoma of the body and tail of the pancreas still remains the disease form with the worst prognosis and evolution.
  • In spite of a huge improvement in diagnostic methods, anaesthetic and surgical procedures and pre- and postoperative assistance, the results in terms of early diagnosis and long-term survival have been generally disappointing.
  • The authors describe their own experience regarding three such tumours treated in five years, analysing the literature data, and referring to the current guidelines in diagnostics and surgical therapy.
  • The difficulty of obtaining an early diagnosis of the disease which derives from many factors, such as unspecific and late appearing symptoms, is stressed.
  • They conclude by confirming the need to perform a radical resection, if possible, which, together with a combination of radio- and chemotherapy, is the only procedure capable of holding out some hope of a cure.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11723900.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 43
  •  go-up   go-down


34. Kitasato A, Tajima Y, Kuroki T, Tsutsumi R, Tsuneoka N, Adachi T, Mishima T, Kanematsu T: Limited pancreatectomy for metastatic pancreatic tumors from renal cell carcinoma. Hepatogastroenterology; 2010 Mar-Apr;57(98):354-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited pancreatectomy for metastatic pancreatic tumors from renal cell carcinoma.
  • BACKGROUND/AIMS: Metastasis of renal cell carcinoma (RCC) to distant organs occurs commonly, even after radical nephrectomy, but metastatic lesions are rarely detected in the pancreas.
  • The present study aim was to improve the postoperative quality of life of a patient with pancreatic metastasis of RCC through limited resection of the pancreas.
  • METHODOLOGY: Since therapeutic modalities including chemotherapy or radiation are ineffective for metastatic tumors, surgical intervention is a treatment of choice in selected patients.
  • In patients with multiple pancreatic metastases, however, near-total or total pancreatectomy may result in a lower quality of life postoperatively due to endocrine and exocrine pancreatic insufficiency.
  • RESULTS: We used limited resection of the pancreas combined with removal of the uncinate process and distal pancreatectomy for a 65-year-old woman with multifocal pancreatic metastases located in the uncinate process, body, and tail of the pancreas, which were detected 6 years after radical nephrectomy for RCC.
  • This surgical procedure allowed preservation of about 40% of the pancreatic parenchyma, with complete excision of metastatic tumors in the pancreas.
  • CONCLUSIONS: The patient has had an excellent quality of life with well-preserved pancreatic function and no evidence of tumor recurrence for 31 months after pancreatic surgery.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / pathology. Pancreatectomy / methods. Pancreatic Neoplasms / secondary. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Staging. Nephrectomy. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583442.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


35. Egorov AV, Kuzin NM, Kondrashin SA, Lotov AN, Kazantseva IA, Kuznetsov NS, Gurevich LE, Lakreeva MG: [Treatment of malignant pancreatic islet cell tumors]. Khirurgiia (Mosk); 2000;(5):13-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of malignant pancreatic islet cell tumors].
  • Among 142 patients with islet cell tumor who were admitted to hospital between 1982 and 1999, 15 patients (10.6%) had malignant tumours.
  • Islet cell tumors were located in the head and corpus of the pancreas in 26.6% and 26.6% of the patients, respectively, in the tail of the pancreas in 46.8% of the patients.
  • The mean size of the tumor was 2.9 +/- 0.7 cm, in 6 patients (40%) liver metastases were found.
  • US, CT and angiography which sensitivity were 72.7, 100 and 85.7%, respectively, were used for topical diagnosis of the islet cell tumors.
  • Surgical procedures included distal pancreatic resection (n = 11), enucleation of the tumor (n = 2), hepatic resection (n = 1), abdominal exploration (n = 1).
  • In 2 patients palliative pancreatic resections were combined with transarterial embolization and devascularisation of the liver metastases and 2 patients were treated by systemic chemotherapy.
  • In other cases to determine the diagnosis was possible only after planned histological identification of the resected specimens.
  • 5-year survival rates after conservative and surgical treatment were 33% and 62.5%, respectively.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Islet Cell / therapy. Chemoembolization, Therapeutic. Pancreatectomy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Female. Humans. Liver Neoplasms / mortality. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10842959.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] RUSSIA
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


36. Okamoto N, Inaba K, Konno H: [Continuous treatment with S-1, an effective strategy for an older adult with unresectable advanced pancreatic cancer with peritoneal dissemination-a case report]. Gan To Kagaku Ryoho; 2009 Jul;36(7):1187-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Continuous treatment with S-1, an effective strategy for an older adult with unresectable advanced pancreatic cancer with peritoneal dissemination-a case report].
  • The prognosis for advanced pancreatic cancer with peritoneal dissemination is extremely poor, and no effective standard therapy has been established.
  • We present a case of a very old patient whose QOL improved shortly after administration of only S-1 to treat advanced pancreatic cancer with peritoneal dissemination.
  • CT scanning showed severe ascites and a low-density area 2 cm wide at the tail of the pancreas.
  • Ascitic cytology revealed adenocarcinoma and carcinomatous peritonitis due to pancreatic cancer.
  • His abdominal circumference decreased and his appetite improved by 14 days following commencement of the therapy.
  • The blood examination one month following commencement showed a significant decrease in the tumor marker.
  • There was no adverse drug reaction.
  • Six months later CT scanning showed that the ascites had disappeared and that the low-density area at the tail of the pancreas had become less obvious.
  • The tumor marker and biochemical parameters were within standard ranges.
  • Twelve months since the therapy began: there still has been no adverse drug reaction and his QOL has been good.
  • He is receiving the therapy as an outpatient.
  • This case suggests that S-1 is a safe and effective drug for very elderly patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Pancreatic Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Administration, Oral. Aged, 80 and over. Drug Combinations. Humans. Male. Peritoneum / pathology. Peritonitis / etiology. Quality of Life

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620815.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


37. Diaconu C, Mateescu D, Bălăceanu A, Marcu M, Jianu V, Stănică A: Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case report. J Med Life; 2010 Jan-Mar;3(1):96-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case report.
  • CONTEXT: The complex of symptoms in pancreatic cancer is vague, which often delays presentation and diagnosis.
  • Thrombophlebitis is an unusual presentation of pancreatic cancer, which appears more frequent in the cancer of the body and tail of the pancreas.
  • The head of the pancreas was normal, the body and the tail could not be seen very well due to flatulence.
  • After computed tomography, the diagnosis was "Pancreatic tumor with multiple hepatic metastases (stage IV)".
  • At the end of the seventh month of treatment, the patient suffered an irreversible ischemic cardiac event.
  • CONCLUSION: Superficial thrombophlebitis can be the initial manifestation of the pancreatic cancer.
  • Gemcitabine and erlotinib is now a FDA approved regimen for patients with metastatic pancreatic cancer.
  • While the search for the best gemcitabine based backbone for advanced pancreatic cancer continues, studies of anti-angiogenic agents alone or in combination with traditional chemotherapy, should be undertaken, as they may improve overall survival in this group of poor prognosis patients.
  • [MeSH-major] Pancreatic Neoplasms / drug therapy. Paraneoplastic Syndromes / etiology. Thrombophlebitis / etiology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5235-46 [16051966.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1425-33 [16012181.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3187-205 [16682719.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • (PMID = 20302205.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC3019029
  •  go-up   go-down


38. Onishi T, Igarashi T, Ichikawa T: [Case of retroperitoneal fibrosis after surgical treatment of autoimmune pancreatitis]. Hinyokika Kiyo; 2009 Sep;55(9):551-4
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of retroperitoneal fibrosis after surgical treatment of autoimmune pancreatitis].
  • During the routine follow-up for colon cancer, a swollen pancreas tail was detected on enhanced CT.
  • He received distal pancreatectomy under the diagnosis of pancreas cancer on 4th October, 2007.
  • Pathological diagnosis revealed the autoimmune pancreatitis.
  • Eight months later, right hydronephrosis was observed in an abdominal ultrasonographic study, and at the same time, right hydroureterosis due to retroperitoneal soft tissue mass around the bifurcation was detected on enhanced CT.
  • He was treated with predonisolone aiming at the diagnosis and/or therapy.
  • Now, it is thought that autoimmune pancreatitis is a systemic sclerosing disease accompanied with extra-pancreatic pathologic changes such as RPF.
  • [MeSH-major] Autoimmune Diseases / complications. Pancreatitis / complications. Retroperitoneal Fibrosis / diagnosis. Retroperitoneal Fibrosis / etiology
  • [MeSH-minor] Aged. Colonic Neoplasms / complications. Humans. Hydronephrosis / drug therapy. Hydronephrosis / etiology. Immunoglobulin G. Male. Pancreatectomy. Prednisolone / therapeutic use


39. Snajdauf J, Rygl M, Petru O, Kalousova J, Kuklova P, Mixa V, Keil R, Hribal Z: Duodenum-sparing technique of head resection in solid pseudopapillary tumor of the pancreas in children. Eur J Pediatr Surg; 2009 Dec;19(6):354-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenum-sparing technique of head resection in solid pseudopapillary tumor of the pancreas in children.
  • AIM OF STUDY: Aim of the study was to assess the complications and long-term results in children operated on for solid pseudopapillary tumor of the pancreas (SPTP) between 1993-2008 at the authors' institution with a focus on a novel duodenum-sparing technique to treat tumors of the head of the pancreas.
  • METHODS: Retrospective analysis was performed of patient data including demographics, diagnostic measures, the operative technique focusing on tumor of the head of the pancreas, complications and long-term results.
  • In 7 patients the tumor was localized in the head of the pancreas, in 4 patients in the tail, and in 2 patients both the body and tail were involved.
  • Patients with body and tail involvement underwent distal pancreatic resection.
  • In 6 patients with head involvement a duodenum-sparing resection of the head and end-to-end anastomosis of the excluded jejunal loop either to the corpus or tail of the pancreas were performed.
  • She developed a biliary fistula which closed after three weeks with endoscopic stenting.
  • One patient with head resection developed a biliary fistula which closed after two weeks of stenting.
  • One patient who underwent resection of the pancreatic head complained of recurrent abdominal pain one year postoperatively.
  • All patients are alive without tumor recurrence at 6 months to 16 years after operation.
  • CONCLUSION: SPTP is a rare pancreatic tumor with a low degree of malignancy.
  • No perioperative chemotherapy is necessary.
  • [MeSH-major] Biliary Fistula / etiology. Carcinoma, Papillary / surgery. Duodenum. Pancreatectomy / adverse effects. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 19821226.001).
  • [ISSN] 1439-359X
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. Lee HY, Lee DG, Chun K, Lee S, Song SY: Clear cell carcinoma of the pancreas--a case report and review of the literature. Cancer Res Treat; 2009 Sep;41(3):175-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the pancreas--a case report and review of the literature.
  • Most of the malignant neoplasms of the pancreas demonstrate features that are consistent with adenocarcinoma.
  • According to the WHO classification, primary clear cell carcinoma of the pancreas is rare and it is classified as a "miscellaneous" carcinoma.
  • We report here on an unusual case of primary pancreatic clear cell carcinoma, which is the first such reported case in Korea.
  • On the abdominal computed tomography (CT), we detected an abdominal mass involving the pancreas tail and liver, and clear cell carcinoma with rhabdoid feature was seen on the histologic evaluation.
  • The tumor cells showed well defined cell membranes, clear cytoplasm and prominent cell boundaries.
  • She was diagnosed with a primary pancreatic clear cell carcinoma with hepatic metastasis and she received palliative gemcitabine chemotherapy.
  • The patient died one month later of pancreatic cancer progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2008 Sep;21(9):1075-83 [18536653.001]
  • [Cites] JOP. 2007;8(3):330-4 [17495363.001]
  • [Cites] Histopathology. 1998 May;32(5):444-8 [9639120.001]
  • [Cites] Semin Diagn Pathol. 1997 Aug;14(3):213-9 [9279977.001]
  • [Cites] Semin Diagn Pathol. 1997 Aug;14(3):183-202 [9279975.001]
  • [Cites] Ann Diagn Pathol. 2002 Dec;6(6):381-4 [12478490.001]
  • [Cites] Arch Pathol Lab Med. 1989 Feb;113(2):113-4 [2916901.001]
  • [Cites] Acta Pathol Jpn. 1987 Sep;37(9):1521-6 [3687432.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jun;128(6):693-6 [15163226.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(2):140-4 [15127279.001]
  • [Cites] Gastroenterology. 1991 Jan;100(1):233-8 [1983826.001]
  • (PMID = 19809568.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2757667
  • [Keywords] NOTNLM ; Clear cell carcinoma / Pancreas / Rhabdoid tumor
  •  go-up   go-down


41. Baba H, Endo M, Arii S: [Gemcitabine infusion via splenic artery for advanced pancreatic cancer]. Gan To Kagaku Ryoho; 2003 Oct;30(11):1689-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gemcitabine infusion via splenic artery for advanced pancreatic cancer].
  • CT scanning revealed an avascular tumor at the tail of the pancreas measuring 53 x 52 x 50 mm.
  • During laparotomy, the tumor was deemed unresectable and insertion of a catheter in the splenic artery was carried out for postoperative arterial chemotherapy.
  • Gemcitabine (GEM) was administered 1,000 mg 3 times in 2 months via the subcutaneous port connected to the catheter.
  • Decrease in tumor size was observed and serum CEA level dropped to 16.7 ng/ml.
  • In the outpatient setting, 500 mg of GEM was administered several times.
  • One year has passed since the initial treatment, and while the tumor is slowly enlarging, no liver metastasis has been observed.
  • In conclusion, arterial chemotherapy using GEM for advanced pancreatic cancer may be beneficial for patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14619495.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


42. Sezgin C, Karabulut B, Uslu R, Sanli UA, Goksel G, Yuzer Y, Goker E: Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. Scand J Gastroenterol; 2005 Dec;40(12):1486-92
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors.
  • OBJECTIVE: Most patients with pancreatic cancer show an inoperable locally advanced/ metastatic tumour at the time of diagnosis.
  • The present study was aimed at determining the prognostic factors in patients with advanced pancreatic carcinoma treated with gemcitabine.
  • MATERIAL AND METHODS: Sixty-seven unresectable or metastatic pancreatic cancer patients treated with gemcitabine were included in the study and a total of 258 cycles of treatment were applied.
  • Univariate analysis revealed that worse results were found in patients with performance status (PS) = 2, and in patients with primary tumour location in the body or tail of the pancreas (p<0.05).
  • CONCLUSIONS: Low PS is a negative predictive factor for the survival of patients with advanced pancreatic carcinoma treated with gemcitabine.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma / drug therapy. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Health Status Indicators. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16293561.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


43. Catani M, De Milito R, Simi M: [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location]. Chir Ital; 2005 Jan-Feb;57(1):127-33
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location].
  • [Transliterated title] Nuovi orientamenti nella cura dei tumori stromali gastroenterici (GIST) avanzati e metastatici: trattamento combinato intervento chirurgico-terapia sistemica con imatinib in un caso a localizzazione primitiva gastrica.
  • Gastrointestinal stromal tumours (GIST) are rare neoplasms originating from connective tissue in the digestive tract with an incidence of less than 1% and account for most non-epithelial primitive digestive tumours.
  • Metastasis diagnosed at the time of disease discovery confirms GIST malignancy.
  • Resistance to conventional chemotherapy is commonly shown by malignant GIST.
  • Most patients with advanced malignant GIST achieve clinical benefit with imatinib mesilate, an orally administered selective inhibitor of the tyrosine kinase receptor.
  • At the time of the first operation the patient had lost 10 kg body weight over the previous months and was seriously cachectic.
  • Considering the action mechanism of imatinib and the extent of the lesion we decided to perform a total gastrectomy procedure.
  • At the time of the operation the stomach seemed to have a modified volume and shape: it appeared to be divided into two sacs, the larger and deeper of which was the original gastric cavity, while the superficial, smaller one seemed to be a protrusion of the organ.
  • The stomach was indistinguishable from the spleen, the transverse colon and the distal pancreatic tract.
  • The neoplasm was directly linked to the left liver and to the inferior diaphragmatic surface.
  • We performed total gastrectomy and resection of the tail of the pancreas, the spleen, and the transverse colon all in one and the same session.
  • The patient was discharged on postoperative day 8 and commenced imatinib therapy 30 days after the operation with 4 tablets per day.
  • One year after the operation the outcome appears to be lasting and the patient has tolerated the drug treatment well.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrectomy. Gastrointestinal Stromal Tumors / therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Benzamides. Humans. Imatinib Mesylate. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832750.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


44. Yang F, Jin C, Long J, Yu XJ, Xu J, Di Y, Li J, Fu de L, Ni QX: Solid pseudopapillary tumor of the pancreas: a case series of 26 consecutive patients. Am J Surg; 2009 Aug;198(2):210-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid pseudopapillary tumor of the pancreas: a case series of 26 consecutive patients.
  • OBJECTIVE: Solid pseudopapillary tumor (SPT) of the pancreas, which predominantly affects young women, is a relatively indolent entity with favorable prognosis.
  • Clinicopathologic factors were compared between benign and malignant cases to determine what features of the tumor could suggest malignant potential.
  • The neoplasm was localized in the pancreatic head/neck in 14 patients and in the body/tail in 12 patients.
  • All of the tumors-including 8 pancreaticoduodenectomies, 10 distal pancreatectomies, 6 local resections, 1 total pancreatectomy, and 1 central pancreatectomy-were resected successfully.
  • No patient received chemotherapy or radiotherapy after surgery.
  • One of the 2 patients with malignant SPT, in whom Ki-67 immunoreactivity was >25%, developed local recurrence with liver metastasis 4 months and died 6 months after surgery.
  • CONCLUSIONS: SPT is a rare neoplasm with low malignant potential.
  • Characteristic computed axial tomography and magnetic resonance imaging scans combined with age and sex profile should be sufficient for the decision to operate.
  • Patients with malignant SPT should have careful follow-up.
  • The high proliferative index assessed by immunohistochemical staining for Ki-67 may predict poor outcome of malignant SPT.
  • [MeSH-major] Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19268906.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Manfredi R, Graziani R, Cicero C, Frulloni L, Carbognin G, Mantovani W, Mucelli RP: Autoimmune pancreatitis: CT patterns and their changes after steroid treatment. Radiology; 2008 May;247(2):435-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune pancreatitis: CT patterns and their changes after steroid treatment.
  • PURPOSE: To retrospectively evaluate the computed tomographic (CT) patterns of autoimmune pancreatitis (AIP) and their changes after steroid therapy.
  • The medical and imaging data of 21 patients (13 men, eight women; mean age, 47.5 years; age range, 25-79 years) with histopathologically proved AIP who underwent contrast material-enhanced CT at diagnosis and after steroid treatment were included in this study.
  • Image analysis included assessment of the (a) presence or absence and type (focal or diffuse) of pancreatic parenchyma enlargement, (b) contrast enhancement of pancreatic parenchyma, (c) size of the main pancreatic duct (MPD) within the lesion and upstream, and (d) pancreatic parenchyma thickness in the head, body, and tail of the pancreas.
  • RESULTS: Pancreatic parenchyma showed focal enlargement in 14 (67%) patients and diffuse enlargement in seven (33%).
  • Pancreatic parenchyma affected by AIP appeared hypoattenuating in 19 (90%) patients and isoattenuating in two (10%).
  • During the portal venous phase, pancreatic parenchyma showed contrast material retention in 18 (86%) patients and contrast material washout in three (14%).
  • After treatment, there was a reduction in the size of pancreatic parenchyma segments affected by AIP (P < .05).
  • Fifteen (71%) of the 21 patients had a normal enhancement pattern in the pancreatic parenchyma, whereas the enhancement pattern remained hypovascular in six (29%).
  • CONCLUSION: AIP appeared as pancreatic parenchyma enlargement, with MPD stenosis within the lesion and upstream dilatation in focal forms of AIP.
  • After steroid treatment, there was normalization of these findings.
  • [MeSH-major] Autoimmune Diseases / drug therapy. Autoimmune Diseases / radiography. Pancreatitis / drug therapy. Pancreatitis / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Contrast Media. Diatrizoate Meglumine. Female. Glucocorticoids / therapeutic use. Humans. Iohexol / analogs & derivatives. Male. Middle Aged. Prednisone / therapeutic use. Radiographic Image Interpretation, Computer-Assisted. Risk Factors. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • (PMID = 18430876.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Glucocorticoids; 3X9MR4N98U / Diatrizoate Meglumine; 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide; VB0R961HZT / Prednisone
  •  go-up   go-down


46. Kitami CE, Shimizu T, Sato O, Kurosaki I, Mori S, Yanagisawa Y, Ajioka Y, Hatakeyama K: Malignant islet cell tumor projecting into the main pancreatic duct. J Hepatobiliary Pancreat Surg; 2000;7(5):529-33
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant islet cell tumor projecting into the main pancreatic duct.
  • We report herein a rare case of islet cell tumor showing a unique growth pattern in a patient who developed repeated acute pancreatitis as the tumor's initial symptom.
  • Preoperative imaging examinations showed dilatation of the main pancreatic duct (MPD) and cysts around the pancreatic tail.
  • A distal pancreatectomy with splenectomy was performed because the pancreatitis was localized in the distal pancreas and was not controlled by various drug therapies.
  • Grossly, the tumor consisted of two component parts: a markedly infiltrative part in the pancreatic parenchyma, and a papillary elevated part in the MPD.
  • The MPD was obstructed by the tumor spreading widely along the distal MPD.
  • Microscopically, the tumor was composed entirely of islet cell tumors (nonfunctioning), with several foci of venous and lymphatic involvement.
  • Based on its growth behavior, we assumed that the tumor may have arisen from the MPD or from islet cells closely adjacent to the MPD.
  • We discuss the growth pattern of the tumor and the cause of the pancreatitis.
  • [MeSH-major] Carcinoma, Islet Cell / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Acute Disease. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pancreatectomy. Pancreatitis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11180883.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 22
  •  go-up   go-down


47. Dineen SP, Sullivan LA, Beck AW, Miller AF, Carbon JG, Mamluk R, Wong H, Brekken RA: The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer; 2008;8:352
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
  • BACKGROUND: Pancreatic cancer continues to have a 5-year survival of less than 5%.
  • Therefore, more effective therapies are necessary to improve prognosis in this disease.
  • Angiogenesis is required for tumor growth, and subsequently, mediators of angiogenesis are attractive targets for therapy.
  • Vascular endothelial growth factor (VEGF) is a well-characterized mediator of tumor angiogenesis that functions primarily by binding and activating VEGF receptor 2 (VEGFR2).
  • METHODS: The efficacy of CT-322 was evaluated in vivo using two orthotopic pancreatic tumor models.
  • The first model was a human tumor xenograft where MiaPaCa-2 cells were injected into the tail of the pancreas of nude mice.
  • The second model was a syngeneic tumor using Pan02 cells injected into pancreas of C57BL/6J mice.
  • In both models, therapy was initiated once primary tumors were established.
  • Gemcitabine alone or in combination with CT-322 was added to the treatment regimen of mice bearing Pan02 tumors.
  • Therapy was given twice a week for six weeks, after which the animals were sacrificed and evaluated (grossly and histologically) for primary and metastatic tumor burden.
  • RESULTS: Treatment with CT-322 was effective at preventing pancreatic tumor growth and metastasis in orthotopic xenograft and syngeneic models of pancreatic cancer.
  • Additionally, CT-322 treatment increased apoptosis, reduced microvessel density and reduced the number of VEGF-activated blood vessels in tumors.
  • Finally, CT-322, in combination with gemcitabine was safe and effective at controlling the growth of syngeneic pancreatic tumors in immunocompetent mice.
  • CONCLUSION: We conclude that CT-322 is an effective anti-VEGFR2 agent and that further investigation of CT-322 for the treatment of pancreatic cancer is warranted.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Neovascularization, Pathologic / drug therapy. Pancreatic Neoplasms / drug therapy. Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Line, Tumor. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacology. Deoxycytidine / therapeutic use. Disease Models, Animal. Female. Humans. Mice. Mice, Inbred C57BL. Mice, Nude. Necrosis. Neoplasm Metastasis / drug therapy. Treatment Outcome. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 2.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] J Hematol Oncol. 2008;1:20 [18959794.001]
  • [Cites] Blood. 2001 Feb 1;97(3):785-91 [11157498.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):391-400 [15136787.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Dev Dyn. 1995 Apr;202(4):325-32 [7626790.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1952-9 [9581838.001]
  • [Cites] Clin Sci (Lond). 2005 Sep;109(3):227-41 [16104843.001]
  • [Cites] Protein Eng Des Sel. 2005 Sep;18(9):435-44 [16087651.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):24-40 [16407877.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2639-43 [16353142.001]
  • [Cites] Chem Biol. 2006 May;13(5):549-56 [16720276.001]
  • [Cites] Curr Opin Biotechnol. 2006 Dec;17(6):653-8 [17055245.001]
  • [Cites] Mol Divers. 2006 Nov;10(4):515-27 [16972015.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Nat Rev Drug Discov. 2007 Apr;6(4):273-86 [17396134.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):179-213 [17324579.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] N Engl J Med. 2008 May 8;358(19):2039-49 [18463380.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3088-95 [10850461.001]
  • (PMID = 19038046.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ PMC2627916
  •  go-up   go-down


48. Ogura Y, Mizumoto K, Tanaka M, Ohuchida K, Murakami M, Yamada D, Ishikawa N, Nagai E: Strategy for prevention of local recurrence of pancreatic cancer after pancreatectomy: antitumor effect of gemcitabine mixed with fibrin glue in an orthotopic nude mouse model. Surgery; 2006 Jul;140(1):66-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategy for prevention of local recurrence of pancreatic cancer after pancreatectomy: antitumor effect of gemcitabine mixed with fibrin glue in an orthotopic nude mouse model.
  • BACKGROUND: Pancreatic cancer frequently recurs after operative treatment, resulting in a poor prognosis.
  • Inhibition of proliferation of residual cancer cells is important for improved survival of patients with pancreatic cancer.
  • Fibrin glue (FG) is a biocompatible, adherent hemostat that can deliver high concentrations of anticancer drugs to residual cancer cells.
  • The aim of this study was to evaluate the local antitumor effect of a mixture of gemcitabine (GEM) and FG on pancreatic cancer cells implanted orthotopically in nude mice.
  • METHODS: SUIT-2 human pancreatic cells were injected into the tail of the pancreas of nude mice.
  • RESULTS: Twenty-eight days after cell injections, tumor volumes of groups treated with GEM + FG + GEM2,3, GEM1,2,3, GEM + FG, GEM1, and FG were decreased by 84%, 70%, 62%, 37%, and 10%, respectively, compared to that of control mice.
  • CONCLUSIONS: A mixture of GEM and FG was effective in inhibiting the growth of orthotopically implanted pancreatic neoplasms in nude mice.
  • This procedure may be useful clinically to prevent the local recurrence of pancreatic cancer after pancreatectomy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Deoxycytidine / analogs & derivatives. Fibrin Tissue Adhesive / administration & dosage. Neoplasm Recurrence, Local / prevention & control. Pancreatectomy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Animals. Cell Line, Tumor. Combined Modality Therapy. Fluorescent Dyes / administration & dosage. Fluorescent Dyes / pharmacokinetics. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Rhodamines / administration & dosage. Rhodamines / pharmacokinetics. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. RHODAMINE B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857444.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fibrin Tissue Adhesive; 0 / Fluorescent Dyes; 0 / Rhodamines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; K7G5SCF8IL / rhodamine B
  •  go-up   go-down


49. Sheng L, Weixia Z, Longhai Y, Jinming Y: Clinical and biologic analysis of pancreatoblastoma. Pancreas; 2005 Jan;30(1):87-90
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the first description of pancreatoblastoma as a malignant pancreatic tumor of childhood in 1957, approximately 200 cases have been reported.
  • During laparotomy, a 10 x 8 x 8-cm3 tumor was discovered in the pancreatic body and tail, and with 3 cystic masses, 15, 10, and 8 cm in diameter, respectively, involving the right lobe of the liver.
  • Pathologic examination of the resected tumor revealed findings characteristic of pancreatoblastoma.
  • The tumor formed acinar and glandular structures and solid areas and contained many "squamoid corpuscles," a defining feature of pancreatoblastoma.
  • In spite of adjuvant chemotherapy with Adriamycin and gemcitabine, the patient returned 11 months later with several large hepatic masses, invading the pancreatic head and enlarged tracheobronchial lymph nodes.
  • Radiotherapy, transcatheter arterial embolization therapy, and chemotherapy were performed.
  • Unfortunately, the patient died 26 months later from disseminated tumor progression.
  • A review of the literature reveals that pancreatoblastoma in childhood must be considered malignant but usually has a favorable prognosis in contrast to pancreatic neoplasms in adult patients.
  • Biologic study will investigate the molecular biology of this rare tumor.
  • The biology may help define prognosis and therapy for this kind of tumor.
  • [MeSH-major] Pancreas / pathology. Pancreas / radiography. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / radiography

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15632705.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Sváb J, Pesková M, Krusina L, Skrha J, Sindelka G: [Personal experience with surgical treatment of insulinoma]. Rozhl Chir; 2001 Feb;80(2):77-81
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Personal experience with surgical treatment of insulinoma].
  • In 42 a localized tumour was removed, in one diffuse adenomatosis was involved.
  • In three of the operated patients a malignant, enddocrinologically active insulinoma was confirmed.
  • For localization of the tumour before operation US, CT and angiographic examinations were used.
  • The tumour was found in the head of the pancreas in 13 patients (31%), in the body of the pancreas in 14 (33%) and in the tail of the pancreas in 15 (36%).
  • A total of 17 patients (8 after surgery and 9 without surgery) were successfully treated with diazoxide, in 9 patients this treatment is still administered.
  • Pharmacological treatment is therefore justified only in the first group of patients.
  • Our experience indicates that a surgical approach is suitable when the diagnosis is unequivocal, even when there is a negative topographic finding of imaging methods as in 33% of the operated patients the insulinoma was detected only on operation.
  • [MeSH-major] Insulinoma / surgery. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Insulinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12881920.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


51. Welsch T, Büchler MW, Schmidt J: [Surgery for pancreatic cancer]. Z Gastroenterol; 2008 Dec;46(12):1393-403
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery for pancreatic cancer].
  • [Transliterated title] Chirurgie des Pankreaskarzinoms.
  • Ductal pancreatic carcinomas are currently the fourth most common fatal cancer disease with a survival rate of less than 5 % when all stages are considered.
  • Other malignant pancreatic tumours have markedly better prognoses.
  • Even after complete resection and adjuvant chemotherapy, the 5-year survival rate amounts to merely 20 - 25%.
  • Besides a high resistance to chemotherapy and early lympho- and haematogenic metastases, the reason for this is often tumour extension beyond the medial and dorsal resection margins.
  • In standardised pathological examinations cancer cells can be detected in the resection margins in about 75 % of the cases, which reflect the aggressive and infiltrative tumour growth and probably explains the high rate of local recurrence.
  • Standard operations for curative tumour resection are the pylorus-preserving pancreatoduodenectomy (PPPD) and the left pancreatic resection with splenectomy in cases of pancreas tail tumours.
  • Considering surgical complications, pancreatic fistulas with a prevalence of up to 10 % play a decisive role.
  • The technique of the pancreatic anastomosis as well as closure of the pancreatic tail thus represents major surgical challenges.
  • In view of the high recurrence rate of pancreatic carcinomas, extended surgical procedures have been examined in numerous studies.
  • In selected, individual cases, patients may benefit from neoadjuvant radiochemotherapy to down-stage an unresectable tumour with subsequent tumour resection, a metastasis resection, or a resection of a local recurrence.
  • An R0 resection and tumour-free lymph nodes (N0 stage) are the two factors that can provide the best prognosis for the patient with a median survival of 2 years and a good quality of life.
  • Pancreas surgery is being increasingly oriented to the evidence-based data from randomised, controlled studies.
  • In order to achieve a further and urgently needed improvement in treatment results, one should consider, if possible, all suitable patients for enrolment in current clinical studies on neoadjuvant, surgical, or adjuvant therapy.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Humans. Lymph Node Excision. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pancreaticoduodenectomy / methods. Prognosis. Splenectomy / methods. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19053009.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 101
  •  go-up   go-down


52. Rykowski JJ, Hilgier M: Efficacy of neurolytic celiac plexus block in varying locations of pancreatic cancer: influence on pain relief. Anesthesiology; 2000 Feb;92(2):347-54
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of neurolytic celiac plexus block in varying locations of pancreatic cancer: influence on pain relief.
  • BACKGROUND: Neurolytic celiac plexus block (NCPB) is an effective way of treating severe pain in some patients with pancreatic malignancy.
  • However, there are no studies to date that evaluate the effectiveness of NCPB related to the site of primary pancreas cancer.
  • The aim of the study was to assess the effectiveness of NCPB in pancreatic cancer pain, depending on the location of the pancreatic tumor.
  • METHODS: The prospective study was conducted in 50 consecutive patients diagnosed with pancreatic cancer.
  • The patients were categorized into two different groups depending on tumor localization: group 1: patients with the cancer of the head of the pancreas and group 2: patients with the cancer of the body and tail of the pancreas.
  • Those patients were scheduled for repeated retrocrural neurolysis during computed tomography control.
  • Computed tomography showed massive growth of the tumor around the celiac axis with metastases.
  • After repeated neurolysis, pain relief clinically still was not satisfactory, necessitating additional opioid treatment.
  • CONCLUSION: In this study, unilateral transcrural celiac plexus neurolysis has been shown to provide effective pain relief in 74% of patients with pancreatic cancer pain.
  • Neurolysis was more effective in cases with tumor involving the head of the pancreas.
  • In the cases with advanced tumor proliferation, regardless of the technique used, the analgesic effects of NCPB were not satisfactory.
  • [MeSH-major] Celiac Plexus. Nerve Block. Pain, Intractable / drug therapy. Pancreatic Neoplasms / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anesthetics, Local. Bupivacaine. Female. Humans. Male. Middle Aged. Pain Measurement. Prospective Studies. Survival. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10691219.001).
  • [ISSN] 0003-3022
  • [Journal-full-title] Anesthesiology
  • [ISO-abbreviation] Anesthesiology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anesthetics, Local; Y8335394RO / Bupivacaine
  •  go-up   go-down


53. Nishihara T, Sawada T, Yamamoto A, Yamashita Y, Ho JJ, Kim YS, Chung KH: Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for pancreatic cancer. Jpn J Cancer Res; 2000 Aug;91(8):817-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for pancreatic cancer.
  • In a previous study, mouse monoclonal antibody (MoAb) Nd2 (m-Nd2, mouse IgG1) labeled with (131)I exhibited efficacy in in vivo radioimmunotherapy against pancreatic cancer.
  • Cytotoxicity to pancreatic cancer (PC) cell lines, including Nd2 antigen-positive (SW1990, RWP-1, Capan-1) and Nd2 antigen-negative (Panc-1, MiaPaca-2, Capan-2) lines, was evaluated by mixed human leukocyte and tumor cell culture (MLTC) at an effector cell to target cell (E / T) ratio of 50 with or without Nd2.
  • Cytotoxic capacity during MLTC with c-Nd2 was significantly higher than during MLTC with m-Nd2 or with no antibody.
  • Intraperitoneal injection of c-Nd2 inhibited the tumor growth of SW1990 xenografted subcutaneously in nude mice and prolonged the survival of nude mice in which SW1990 tumor was transplanted orthotopically at the tail of the pancreas.
  • These findings suggested that, because of its ability to induce ADCC, c-Nd2 may be clinically useful for the immunotherapeutic treatment of pancreatic cancer.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Pancreatic Neoplasms / therapy. Recombinant Fusion Proteins / therapeutic use
  • [MeSH-minor] Animals. Antibody Affinity. Antibody-Dependent Cell Cytotoxicity. Disease Models, Animal. Humans. Immunotherapy. Leukocytes, Mononuclear / drug effects. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Transplantation, Heterologous. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10965023.001).
  • [ISSN] 0910-5050
  • [Journal-full-title] Japanese journal of cancer research : Gann
  • [ISO-abbreviation] Jpn. J. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA24321
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


54. Rebhandl W, Felberbauer FX, Puig S, Paya K, Hochschorner S, Barlan M, Horcher E: Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children: report of four cases and review of the literature. J Surg Oncol; 2001 Apr;76(4):289-96
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid-pseudopapillary tumor of the pancreas (Frantz tumor) in children: report of four cases and review of the literature.
  • BACKGROUND: Solid-pseudopapillary tumor of the pancreas (SPT) is an exceptionally rare neoplasm in children.
  • It is of low malignant potential and occurs most frequently in young females.
  • PATIENTS AND METHODS: A cumulative review of the tumor's clinicopathological characteristics from the world's literature is presented.
  • Two tumors were located in the tail, one in the body and tail and one in the head of the pancreas (diameter: 7--15 cm).
  • Surgical procedures included three distal pancreatectomies and one partial duodenopancreatectomy (Whipple procedure).
  • Chemotherapy was initiated for this patient.
  • CONCLUSIONS: SPT is a rare differential diagnosis of a pancreatic mass in children.
  • It is mandatory to establish this diagnosis since complete surgical removal of the tumor even in case of metastases or local invasion offers an excellent prognosis.
  • [MeSH-major] Cystadenoma, Papillary / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11320522.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down






Advertisement